Evaluating Efficacy, Safety, and Tolerability in Patients with Moderate to Severe Cancer-Related Pain

ZYUS Life Sciences Corporation ("ZYUS" or the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, announced today it has made the strategic decision to proceed with a Phase 2 Clinical Trial in Canada to assess the preliminary efficacy, safety and tolerability of Trichomylin softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain.

“Chronic pain is a major unmet medical need for cancer patients and has been linked with an impaired quality of life, lower adherence to treatment and higher healthcare costs,” said Brent Zettl, President and CEO of ZYUS. “This Phase 2 Clinical Trial is a landmark moment in ZYUS’ mission to reimagine the treatment of pain by redefining the standard of care with the development of cannabinoid-based therapies for pain management in pursuit of transformational impact on patients’ lives.”

Transitioning to Phase 2 Clinical Trial forTrichomylin Softgels

Initially planned as a Phase 2a Clinical Trial, ZYUS has made the strategic decision to fast-track and progress directly to a full Phase 2 Clinical Trial following receipt of positive results from its Phase 1, first-in-human clinical trial testing the safety and tolerability of Trichomylin softgel capsules. While a Phase 2a Clinical Trial could...